Ethics committees and funding agencies often receive protocols that involve either too many or too few animals to answer the specific research question being investigated. It is evident that a greater ...

FY25 profit surge, discounted valuation, and ReSPECT Phase III Rezzayo catalyst in Q2 2026. Click for this CRMD update.

Good morning, and welcome to the Akebia Therapeutics R&D Day. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Akebia website following ...

Two multicenter trials drew different conclusions about the value of conduction system relative to biventricular pacing for ...

Ten years after tailored radiotherapy (RT) for breast cancer, fewer than 3% of patients had locoregional recurrences (LRR), ...

There is a lack of studies on lifestyle interventions to improve asthma and allergic disease in women, and Sharmilee M.

A 2026 product overview examining Trimology's RS2 resistant starch formulation, probiotic ingredient research, BioSignal ...

Kujali is an AI-driven decision-support tool that delivers real-time clinical decision support to birth attendants.

Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants ...

BACKGROUND: Premature atrial contractions (PACs) are independently associated with atrial fibrillation, stroke, and heart failure, yet no pharmacological therapy is approved for PAC suppression.

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...

Dyne Therapeutics (NASDAQ:DYN) executives outlined a slate of 2026 operational and regulatory milestones during a discussion ...